-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Ruibo Bio-B (06938.HK) issued an announcement. The company has submitted a Phase I clinical trial application (CTA) in the European Union for the dual-target siRNA drug SR122 (a type of GalNAC-conjugated siRNA therapy for the treatment of dyslipidemia including severe hypertriglyceridemia (SHTG) and mixed dyslipidemia).

Zhitongcaijing·11/09/2026 23:57:16
Listen to the news
Zhitong Finance App News, Ruibo Bio-B (06938.HK) issued an announcement. The company has submitted a Phase I clinical trial application (CTA) in the European Union for the dual-target siRNA drug SR122 (a type of GalNAC-conjugated siRNA therapy for the treatment of dyslipidemia including severe hypertriglyceridemia (SHTG) and mixed dyslipidemia).